Expertise in
10
conditions

Dr. Lauri M. Burroughs

Hematology | Oncology
Seattle Children's Hospital
4800 Sand Point Way NE, 
Seattle, WA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
25 Years of Experience
Expertise in
10
conditions
Seattle Children's Hospital
4800 Sand Point Way NE, 
Seattle, WA 

Overview

Lauri Burroughs is a Hematologist and an Oncologist practicing medicine in Seattle, Washington. She has been practicing medicine for over 25 years.

Dr. Burroughs is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Shwachman-Diamond Syndrome, Aplastic Anemia, Primary Immunodeficiency (PID), Transient Erythroblastopenia of Childhood, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 61 peer reviewed articles and participating in 17 clinical trials. Dr. Burroughs is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatrics in WA

Languages Spoken

English
Hungarian
Japanese
Korean
Spanish

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

PacificSource
  • PPO
Premera
  • EPO
  • PPO

Locations

Seattle Children's Hospital
4800 Sand Point Way NE, Seattle, WA 98105
Other Locations
Fred Hutchinson Cancer Center
1100 Fairview Ave N, Seattle, WA 98109

Additional Areas of Focus

Dr. Burroughs has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Targeted Astatine-211-Labeled BC8-B10 Monoclonal Antibody as Reduced Intensity Conditioning for Nonmalignant Diseases
Targeted Astatine-211-Labeled BC8-B10 Monoclonal Antibody as Reduced Intensity Conditioning for Nonmalignant Diseases
Enrollment Status: Recruiting
Publish Date: June 17, 2026
Intervention Type: Drug, Radiation, Procedure, Biological
Study Phase: Phase 1/Phase 2
A Randomized Trial of Low Versus Moderate Exposure Busulfan for Infants With Severe Combined Immunodeficiency (SCID) Receiving TCRαβ+/CD19+ Depleted Transplantation: A Phase II Study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC)
A Randomized Trial of Low Versus Moderate Exposure Busulfan for Infants With Severe Combined Immunodeficiency (SCID) Receiving TCRαβ+/CD19+ Depleted Transplantation: A Phase II Study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Device
Study Drug: Busulfan
Study Phase: Phase 2
Radiation- and Alkylator-free Hematopoietic Cell Transplantation for Bone Marrow Failure Due to Dyskeratosis Congenita / Telomere Disease
Radiation- and Alkylator-free Hematopoietic Cell Transplantation for Bone Marrow Failure Due to Dyskeratosis Congenita / Telomere Disease
Enrollment Status: Active_not_recruiting
Publish Date: March 27, 2026
Intervention Type: Drug, Biological
Study Drugs: Alemtuzumab, Fludarabine, Cyclosporine, Mycophenolate Mofetil
Study Phase: Phase 2
Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for the Treatment of Bone Marrow Failure Diseases
Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for the Treatment of Bone Marrow Failure Diseases
Enrollment Status: Completed
Publish Date: March 09, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Phase: Phase 2
A Pilot Feasibility Study of Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants Using a Self-Inactivating Lentiviral Vector to Transduce Autologous CD34+ Hematopoietic Cells
A Pilot Feasibility Study of Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants Using a Self-Inactivating Lentiviral Vector to Transduce Autologous CD34+ Hematopoietic Cells
Enrollment Status: Suspended
Publish Date: November 10, 2025
Intervention Type: Device, Genetic, Drug
Study Drugs: Busulfan, Autologous CD34-Positive GammaC-Transduced Lentiviral Bone Marrow Cells
Study Phase: Phase 1/Phase 2
Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia
Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia
Enrollment Status: Completed
Publish Date: May 11, 2025
Intervention Type: Drug, Procedure, Radiation
Study Phase: Not Applicable
A Study Evaluating BPX-501 T Cells and AP1903 for Prevention of Graft Versus Host Disease (GVHD) After Haploidentical, Related, T Cell-Depleted Hematopoietic Cell Transplantation for Non-Malignant Diseases
A Study Evaluating BPX-501 T Cells and AP1903 for Prevention of Graft Versus Host Disease (GVHD) After Haploidentical, Related, T Cell-Depleted Hematopoietic Cell Transplantation for Non-Malignant Diseases
Enrollment Status: Terminated
Publish Date: March 25, 2024
Intervention Type: Biological
Study Drugs: BPX-501, Rimiducid
Study Phase: Phase 1
Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Enrollment Status: Active_not_recruiting
Publish Date: July 12, 2022
Intervention Type: Biological, Drug
Study Drugs: BPX-501 T Cells, Rimiducid
Study Phase: Phase 1/Phase 2
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Enrollment Status: Unknown
Publish Date: September 02, 2021
Allogeneic Hematopoietic Cell Transplantation for Patients With Nonmalignant Inherited Disorders Using a Treosulfan Based Preparative Regimen
Allogeneic Hematopoietic Cell Transplantation for Patients With Nonmalignant Inherited Disorders Using a Treosulfan Based Preparative Regimen
Enrollment Status: Completed
Publish Date: August 13, 2021
Intervention Type: Procedure, Drug, Other, Biological, Radiation
Study Drugs: Anti-Thymocyte Globulin, Cyclosporine, Fludarabine, Methotrexate, Mycophenolate Mofetil, Tacrolimus, Treosulfan
Study Phase: Phase 2
View 9 Less Clinical Trials

61 Total Publications

Comparison of Late Effects and Quality of Life by Donor Type in Long-Term Survivors of Severe Aplastic Anemia after Hematopoietic Cell Transplantation.
Comparison of Late Effects and Quality of Life by Donor Type in Long-Term Survivors of Severe Aplastic Anemia after Hematopoietic Cell Transplantation.
Journal: Transplantation and cellular therapy
Published: April 17, 2026
Similar Doctors
Expertise in
22
conditions
Dr. Douglas S. Hawkins
Hematology | Oncology
Expertise in
22
conditions
Dr. Douglas S. Hawkins
Hematology | Oncology
Referral may be required

Seattle Children's Hospital

4800 Sand Point Way NE, 
Seattle, WA 
 (0.1 miles away)
206-987-2000
Languages Spoken:
English, German
See accepted insurances
Accepting New Patients
Offers Telehealth

Douglas Hawkins is a Hematologist and an Oncologist practicing medicine in Seattle, Washington. Dr. Hawkins is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Rhabdomyosarcoma, Adult Soft Tissue Sarcoma, Osteosarcoma, Osteotomy, and Bone Marrow Aspiration. Dr. Hawkins is currently accepting new patients.

Expertise in
24
conditions
Dr. Sarah S. Leary
Hematology | Oncology
Expertise in
24
conditions
Dr. Sarah S. Leary
Hematology | Oncology
Referral may be required

Seattle Children's Hospital

4800 Sand Point Way NE, 
Seattle, WA 
 (0.1 miles away)
206-987-2106
Languages Spoken:
English, Castilian, French, Hindi, Mandarin, Punjabi, Spanish, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Sarah Leary is a Hematologist and an Oncologist practicing medicine in Seattle, Washington. Dr. Leary is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Medulloblastoma, Glioma, Gliomatosis Cerebri, Brain Tumor, and Bone Marrow Aspiration. Dr. Leary is currently accepting new patients.

Expertise in
11
conditions
Dr. James M. Olson
Hematology | Oncology
Expertise in
11
conditions
Dr. James M. Olson
Hematology | Oncology
Referral may be required

Seattle Children's Hospital

4800 Sand Point Way NE, 
Seattle, WA 
 (0.1 miles away)
206-987-2106
Languages Spoken:
English, Afrikaans, Korean, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

James Olson is a Hematologist and an Oncologist practicing medicine in Seattle, Washington. Dr. Olson is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Posterior Fossa Tumor, and Glioma. Dr. Olson is currently accepting new patients.

Frequently Asked Questions about Dr. Lauri M. Burroughs

How do I make an appointment with Dr. Lauri M. Burroughs?

You can book an appointment with Dr. Lauri M. Burroughs by calling their office at 206-987-2106. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Lauri M. Burroughs a top-rated expert for Shwachman-Diamond Syndrome?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Lauri M. Burroughs is classified as an Distinguished expert for Shwachman-Diamond Syndrome, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Lauri M. Burroughs specialize in?

While Dr. Lauri M. Burroughs is a Hematology, they have specific expertise in Shwachman-Diamond Syndrome, Aplastic Anemia, and Primary Immunodeficiency (PID). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Lauri M. Burroughs participate in research or clinical trials?

Yes. Dr. Lauri M. Burroughs has published 61 articles and abstracts on conditions like Shwachman-Diamond Syndrome. You can view a list of Dr. Lauri M. Burroughs's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Lauri M. Burroughs accept my insurance?

Dr. Lauri M. Burroughs accepts most major insurance plans, including PacificSource and Premera. We recommend calling the office directly at 206-987-2106 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Burroughs's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 18 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile